Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors

12 Feb 2019

Abstract excerpt

Abstract Malignant rhabdoid tumors (MRT) are highly aggressive pediatric cancers that respond poorly to current therapies. In this study, we screened several MRT cell lines with large-scale RNAi, CRISPR-Cas9, and small-molecule libraries to identify potential drug targets specific for these cancers. We discovered MDM2 and MDM4, the canonical negative regulators of p53, as significant vulnerabilities. Using two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30755442
DOI: 10.1158/0008-5472.can-18-3066

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid TumorsPMID 30755442Read ↗

Targeting the p53 pathway to treat Malignant Rhabdoid and Atypical Teratoid Rhabdoid TumorsSemantic proximity Read ↗

Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumorsSemantic proximity Read ↗

p53 Pathway Inactivation Drives SMARCB1 -deficient p53 -wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 InhibitionSemantic proximity Read ↗

Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma.Semantic proximity Read ↗

High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid TumorsSemantic proximity Read ↗

Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis.Semantic proximity Read ↗

A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers.Semantic proximity Read ↗

Spatial dissection of ADC/RPT targets defines therapeutic opportunities in rhabdoid tumorsSemantic proximity Read ↗

Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevanceSemantic proximity Read ↗

Genome-wide CRISPR and small-molecule screens uncover targetable dependencies in ATRTSemantic proximity Read ↗

Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilitiesSemantic proximity Read ↗

Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.